Copertina

The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey

The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecolo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Riedel, Maximilian (Autore) , Herrmann, Helene (Autore) , Bartl, Thomas (Autore) , Rossner, Anna-Maria (Autore) , Tatzber, Anna (Autore) , Flethe, Chiara (Autore) , Zocholl, Dario (Autore) , Schmalfeldt, Barbara (Autore) , Sehouli, Jalid (Autore) , Pietzner, Klaus (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: 29 January 2025
In: BMC cancer
Year: 2025, Volume: 25, Pages: 170-1-170-9
ISSN:1471-2407
DOI:10.1186/s12885-025-13432-5
Accesso online:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-025-13432-5
Testo
Note sull'autore:Maximilian Riedel, Helene Herrmann, Thomas Bartl, Anna-Maria Rossner, Anna Tatzber, Chiara Flethe, Dario Zocholl, Barbara Schmalfeldt, Jalid Sehouli and Klaus Pietzner
Descrizione
Riassunto:The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecologic oncology are very limited. The aim of this survey was to provide a real-world overview of the experiences and the current state of irAE management of ICIs in Germany, Switzerland, and Austria.
Descrizione del documento:Gesehen am 02.10.2025
Descrizione fisica:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-025-13432-5

Documenti analoghi